Starting at Discovery
Hear Vivek Ramaswamy describe how Roivant is leveraging the scale of the pharmaceutical industry, and the mentality of a start-up, to help bring new and powerful medicines to market.
00:00:07
Vivek Ramaswamy
We’re culturally wired a little bit differently to most Pharma companies in that we don’t discover most of our drugs in-house. Rather, we view the entire world as our laboratory – because the real problem as we see it isn’t in the discovery of drugs – that’s happening in an inspiring way. The real problem is taking those discoveries, and translating them into becoming approved medicines that can actually reach patients and impact their lives. And to that end – the process is broken.
00:00:40
Interviewer
How are you different to other pharmaceutical companies?
00:00:42
Vivek Ramaswamy
What we’re trying to do is to borrow from the best of large scale Pharmaceutical companies, and some of the benefits of scale, but to pair that with the benefits of entrepreneurship, of small, scrappy nimble startups.
00:00:53
Vivek Ramaswamy
We build these things called Vants. Effectively, nimble, entrepreneurial, biotech or health tech companies in their own right, with their own leadership teams, their own operating teams that work on specific projects that advance say, a given medicine to patients.
00:01:10
Vivek Ramaswamy
We can work with any partner, any individual academic University, company start-up around the world to help them advance their project by using Roivant’s platform to take an existing discovery through development.
00:01:25
Interviewer
How do you see the industry changing in the near future?
00:01:28
Vivek Ramaswamy
Historically, the pharma industry’s model has been to deliver chronic therapies, drugs that you take once or twice or thrice a day, over the course of your lifetime.
00:01:36
Vivek Ramaswamy
Because of fundamental changes in science and genetic medicine, we’re going to see more one time therapies and even cures.
00:01:44
Vivek Ramaswamy
As a consequence, I think we’re going to see more and more pharma companies, really thinking about problems beyond just developing individual medicines, and moving on to the healthcare of the patient more holistically.
00:01:53
Vivek Ramaswamy
We couldn’t have imagined cures of the kinds that we can deliver with new gene therapies, with new RNA based medicines. Now it’s possible.
00:02:03
Vivek Ramaswamy
And I think we have to really think about a new narrative for what life itself looks like in a world where people are living longer.
IMPORTANT INFORMATION
The information contained in the videos posted on this webpage (the “Information”) serves solely informational purposes, and is not and may not be construed as or relied on in any manner, as legal, business, tax, investment, accounting or other advice or as an offer to sell or a solicitation of an offer to buy limited partnership or comparable limited liability equity interests in SoftBank Vision Fund L.P. (together with, as the context may require, any parallel fund, feeder fund, co-investment vehicle or alternative investment vehicle, “SVF I” or the “Vision Fund I”), or SoftBank Vision Fund II-1 L.P. and SoftBank Vision Fund II-2 L.P. (together with, as the context may require, any parallel fund, feeder fund, co-investment vehicle or alternative investment vehicle, “SVF II” or the “Vision Fund II”, and together with the Vision Fund I, the “Funds”), each managed by SB Investment Advisers (UK) Ltd. (the “Manager” or “SBIA”) and its affiliates. The Information is not intended to be relied upon as the basis for any investment decision, and is not, and should not be assumed to be, complete.
None of the Vision Fund I, Vision Fund II, or any successor fund managed by SBIA, SBIA, SoftBank Group Corp. (together with its affiliates, “SoftBank”) or their respective affiliates makes any representation or warranty, express or implied, as to the accuracy or completeness of the Information and nothing contained therein should be relied upon as a promise or representation as to past or future performance of the Vision Fund I, Vision Fund II or any other entity referenced in the Information or future performance of any successor fund managed by SBIA. SBIA, Softbank or any affiliate of the foregoing or any related person shall have no duty or responsibility to provide the visitors to this webpage with any information regarding the business, operations, property, financial and other condition and creditworthiness of any entities, companies or any of their affiliates to the extent they are discussed therein or to update the Information. Visitors to this webpage accept all risks in relying on the Information or any part thereof for any purpose whatsoever.
Statements contained in the Information (including those relating to current and future market conditions and trends in respect thereof) that are not historical facts are based on current expectations, estimates, projections, opinions and/or beliefs of the individuals making the statements. Such statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon. In addition, no representation or warranty is made with respect to the reasonableness of any estimates, forecasts, illustrations, prospects or returns, which should be regarded as illustrative only, or that any profits will be realized. Certain information contained therein constitutes “forward-looking statements” which can be identified by the use of terms such as “may”, “will”, “should”, “expect”, “project”, “estimate”, “intend”, “continue”, “target” or “believe” (or the negatives thereof) or other variations thereon or comparable terminology. Due to various risks and uncertainties, actual events or results or actual performance of any entity referred to therein may differ materially from those reflected or contemplated in such forward-looking statements. As a result, visitors to this webpage should not rely on such forward-looking statements for any reason. Further, any targets stated therein are based on an assumption that economic, market and other conditions will not deteriorate and, in some cases, improve. These projections involve significant elements of subjective judgement. No representation or warranty is made as to future performance or such forward-looking statements.